AbbVie unveils new Phase 3 upadacitinib data in moderate to severe ulcerative colitis
December 10, 2020Research and Development AbbVie, upadacitinib
AbbVie has announced data from the first of two Phase 3 studies investigating the efficacy of upadacitinib in treating moderate …
Pharmafile.com’s weekly COVID-19 news round-up
December 9, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, Top 5, pharma
COVID-19 vaccine news continues to roll in and continues to be positive, with AstraZeneca now releasing Phase 3 data that …
Novartis’ Kisqali delays need for chemo by over 4 years in post-menopausal HR+HER2- metastatic breast cancer
December 9, 2020Research and Development Kisqali, Novartis, breast cancer
Novartis has lifted the curtain on updated Phase 3 data for Kisqali (ribociclib) in the treatment of hormone receptor positive, …
MHRA warns patients with history of significant allergic reactions not to receive Pfizer/BioNTech COVID-19 vaccine
December 9, 2020Research and Development COVID-19, MHRA, UK, Vaccine
While the rolling out of Pfizer and BioNTech’s COVID-19 in the UK this week marked a historic moment in a …
AstraZeneca and Oxford Uni vaccine is safe and effective in preventing COVID-19 infection, Phase 3 data show
December 9, 2020Research and Development AstraZeneca, COVID-19, Vaccine
The latest efficacy data on the COVID-19 vaccine developed by AstraZeneca in partnership with the University of Oxford have been …
Amryt’s Lojuxta approved in Brazil to reduce cholesterol in homozygous familial hypercholesterolaemia patients
December 9, 2020Research and Development, Sales and Marketing Amryt, Brazil, rare disease
Brazil’s National Health Surveillance Agency (ANVISA) has moved to authorise Amryt’s Lojuxta (lomitapide) in the country as a treatment for …
UK launches COVID-19 vaccination drive with first dosings of Pfizer/BioNTech’s candidate
December 8, 2020Manufacturing and Production, Sales and Marketing COVID-19, UK, Vaccine
The first doses of Pfizer and BioNTech’s approved COVID-19 vaccine have been administered in the UK in a historic occasion …
NICE recommendation for AstraZeneca’s Calquence in chronic lymphocytic leukaemia populations
December 8, 2020Manufacturing and Production, Sales and Marketing AstraZeneca, NHS, NICE, UK, leukaemia
The National Institute for Health and Care Excellence (NICE) has recommended that AstraZeneca’s Calquence (acalabrutinib) be used on the NHS in …
US pharma lobby launches legal action against the Trump administration over drug pricing proposals
December 8, 2020Manufacturing and Production, Sales and Marketing Drug pricing, PhRMA, Trump, US
US industry organisations including the Pharmaceutical Research and Manufacturers of America (PhRMA) have launched legal action against the Trump administration …
South Korea secures enough COVID-19 vaccine doses for 44 million citizens
December 8, 2020Manufacturing and Production, Sales and Marketing COVID-19, Vaccine, south korea
The South Korean Government has announced plans to secure enough COVID-19 vaccine doses to inoculate 44 million of its citizens, …
China approves Takeda’s Takhzyro to prevent hereditary angioedema attacks in patients over 12
December 8, 2020Manufacturing and Production, Sales and Marketing China, Takeda
China’s National Medical Products Administration (NMPA) has given approval in the country for Takeda’s Takhzyro (lanadelumab), in a subcutaneous injection …
Novartis unveils new multi-trial data for CAR-T therapy Kymriah in advanced lymphoma
December 7, 2020Research and Development, Sales and Marketing CAR-T, Kymriah, Novartis
Novartis has taken the opportunity at the 2020 American Society of Hematology Annual Meeting & Exposition (ASH) to unveil promising …
EMA receives filing for Janssen’s twice-yearly schizophrenia jab
December 7, 2020Sales and Marketing EMA, Janssen, schizophrenia
The European Medicines Agency (EMA) has received Janssen’s Marketing Authorisation Extension for paliperidone palmitate six-monthly (PP6M), an injectable therapy administered …
Jakafi outperforms best available therapy in steroid-refractory/dependent chronic graft-versus-host disease
December 7, 2020Research and Development, Sales and Marketing Incyte, Jakafi, Novartis
The first Phase 3 findings have been revealed for Jakafi (ruxolitinib) in the treatment of steroid-refractory or steroid-dependent chronic graft-versus-host disease …
Six-year follow-up data shows Imbruvica’s benefit in high-risk chronic lymphocytic leukaemia
December 7, 2020Research and Development, Sales and Marketing Janssen, chronic lymphocytic leukaemia, imbruvica
Janssen has revealed multiple pooled data analyses for its Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib) in the first-line treatment …
FDA approves Novo Nordisk’s Saxenda for adolescent obesity
December 7, 2020Sales and Marketing FDA, Novo Nordisk, saxenda
The FDA has awarded US approval to Novo Nordisk’s Saxenda (liraglutide) 3mg injection to treat obesity in patients between the …
Top Ten most popular articles on Pharmafile.com this week
December 4, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, Dupixent, EMA, UK, Vaccine, top ten
As the year winds to a close, excitement is rising around the efficacy and availability of COVID-19 vaccines around the …
New research links metformin to decreased mortality risk in female patients hospitalised with COVID-19
December 4, 2020Medical Communications, Research and Development COVID-19, Vaccine, metformin
Researchers from the University of Minnesota Medical School (UMMS) and UnitedHealth Group have uncovered potential benefit of metformin, a generic …
IBM uncovers “precision phishing campaign” targeting global COVID-19 vaccine cold chain supply
December 4, 2020Manufacturing and Production, Medical Communications, Research and Development COVID-19, Vaccine, ibm
US tech firm IBM has reported that it has identified attempts by unknown parties to hack and disrupt elements of …
FDA approves BioCryst’s Orladeyo for reducing hereditary angioedema attacks
December 4, 2020Medical Communications, Sales and Marketing BioCryst, FDA, Orladeyo
BioCryst has scored FDA for its therapy Orladeyo (berotralstat) for reducing or preventing hereditary angioedema (HAE) attacks in patients over …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
